3-4-dihydroxyphenylpropionic-acid and Diabetes-Mellitus--Type-2

3-4-dihydroxyphenylpropionic-acid has been researched along with Diabetes-Mellitus--Type-2* in 2 studies

Trials

1 trial(s) available for 3-4-dihydroxyphenylpropionic-acid and Diabetes-Mellitus--Type-2

ArticleYear
Urinary metabolomics of phenolic compounds reveals biomarkers of type-2 diabetes within the PREDIMED trial.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 162

    Phenolic compounds have been associated with protective effects against type-2 diabetes (T2D). We used a metabolomics approach to determine urinary phenolic metabolites associated with T2D and fasting plasma glucose.. This case-control study within the PREDIMED trial included 200 participants at high cardiovascular risk, 102 of whom were diagnosed with T2D. A panel of urinary phenolic compounds were analysed using a novel method based on liquid chromatography coupled to mass spectrometry. Multivariate statistics and adjusted logistic regressions were applied to determine the most discriminant compounds and their association with T2D. The relationship between the discriminant phenolic compounds and plasma glucose was assessed using multivariable linear regressions.. A total of 41 phenolic compounds were modeled in the orthogonal projection to latent structures discriminant analysis, and after applying adjusted logistic regressions two were selected as discriminant: dihydrocaffeic acid (OR = 0.22 (CI 95 %: 0.09; 0.52) per 1-SD, p-value = 0.021) and genistein diglucuronide (OR = 0.72 (CI 95%: 0.59; 0.88) per 1-SD, p-value = 0.021). Both metabolites were associated with a lower risk of suffering from T2D, but only dihydrocaffeic acid was inversely associated with plasma glucose (β = -17.12 (95 % CI: -29.92; -4.32) mg/dL per 1-SD, p-value = 0.009).. A novel method using a metabolomics approach was developed to analyse a panel of urinary phenolic compounds for potential associations with T2D, and two metabolites, dihydrocaffeic acid and genistein diglucuronide, were found to be associated with a lower risk of this condition.

    Topics: Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Diet, Mediterranean; Genistein; Humans; Metabolomics; Phenols; Risk Factors

2023

Other Studies

1 other study(ies) available for 3-4-dihydroxyphenylpropionic-acid and Diabetes-Mellitus--Type-2

ArticleYear
Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?
    Journal of biomolecular structure & dynamics, 2013, Volume: 31, Issue:11

    Insulin-degrading enzyme (IDE) gene is one of the type 2 diabetes mellitus susceptibility genes specific to the Han Chinese population. IDE, a zinc-metalloendopeptidase, is a potential target for controlling insulin degradation. Potential lead compounds for IDE inhibition were identified from traditional Chinese medicine (TCM) through virtual screening and evaluation of their pharmacokinetic properties of absorption, distribution, metabolism, excretion, and toxicity. Molecular dynamics (MD) simulation was performed to validate the stability of complexes from docking simulation. The top three TCM compounds, dihydrocaffeic acid, isopraeroside IV, and scopolin, formed stable H-bond interactions with key residue Asn139, and were linked to active pocket residues His108, His112, and Glu189 through zinc. Torsion angle trajectories also indicated some stable interactions for each ligand with IDE. Molecular level analysis revealed that the TCM candidates might affect IDE through competitive binding to the active site and steric hindrance. Structural feature analysis reveals that high amounts of hydroxyl groups and carboxylic moieties contribute to anchor the ligand within the complex. Hence, we suggest the top three TCM compounds as potential inhibitor leads against IDE protein to control insulin degradation for type 2 diabetes mellitus. An animated interactive 3D complement (I3DC) is available in Proteopedia at http://proteopedia.org/w/Journal:JBSD:29.

    Topics: Asian People; Binding Sites; Caffeic Acids; Coumarins; Diabetes Mellitus, Type 2; Glucosides; Humans; Hydrogen Bonding; Hypoglycemic Agents; Insulysin; Medicine, Chinese Traditional; Molecular Docking Simulation; Molecular Dynamics Simulation; Structure-Activity Relationship

2013